Chrono Therapeutics has developed SmartStop, a connected wearable and app solution that allows users to log cravings and supplies them with algorithm-calculated nicotine
SmartStop is a wearable device that offers programmable, transdermal nicotine replacement therapy (NRT) in combination with real-time behavioural support.
Research shows that smokers have clear, consistent and predictable daily peak nicotine craving patterns and according to Chrono, SmartStop is designed to automatically vary nicotine levels throughout the day to match those patterns.
The device uses Bluetooth technology to wirelessly communicate with the SmartStop behavioural support mobile app, providing real-time guidance to help smokers cope with cravings as well as a means for promoting compliance to the NRT and overall quit process.
Smokers insert a nicotine cartridge into the SmartStop wearable, put it on before they go to bed and then set their wake-time on the connected app on their smartphone.
The wearable automatically begins transdermal nicotine delivery 90 minutes before smokers wake up, helping to curb the strong morning craving most smokers experience – something other nicotine replacement products cannot do according to Chrono.
Embedded with sensors and Bluetooth, the SmartStop wearable monitors compliance and connects with a companion mobile app that provides real-time behavioural coaching in response to cravings and a nicotine-dosing regimen.
The SmartStop wearable administers additional doses throughout the day according to a pre-programmed algorithm but does not yet have sensors to measure and respond to nicotine levels in individual smokers.
Michael Burke, assistant professor of medicine at the Mayo Clinic School of Medicine and Program Coordinator at the Mayo Clinic Nicotine Dependence Center, is working with Chrono to integrate tailored nicotine delivery with evidence-based, proactive and personalised behavioural strategies to help smokers quit.
Burke, said: “Integrating a smart digital coach that leverages the best in behavioural science with a new and adjustable method to deliver nicotine replacement has the potential to save many thousands of lives by providing new hope and support to people struggling to become tobacco free.”
The smoking cessation solution is the first product targeted to be commercialised from Chrono’s platform, which represents the convergence of optimised drug delivery, embedded sensor technology to monitor compliance, and connected and personalised behavioural support to transform how medicine is delivered and how people achieve their health goals.